| Date | Title | Description |
| 14.09.2024 | Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments | Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatment
In a patient with a heavily pretreated leiomyosarcoma, BT-001 was able to modulate the tumor mic... |
| 22.07.2024 | Transgene et BioInvent présentent un poster sur le virus oncolytique BT-001, à l’ESMO 2024 | Strasbourg, France, et Lund, Suède, le 22 juillet 2024, 8 h 00 – Transgene (Euronext Paris: TNG), société de biotechnologie qui conçoit et développe des immunothérapies contre le cancer reposant sur des vecteurs viraux, et BioInvent Interna... |
| 19.07.2024 | BioStock: BioInvent and MSD to evaluate new metastatic melanoma treatment | BioStock: BioInvent and MSD to evaluate new metastatic melanoma treatment
Fri, Jul 19, 2024 11:00 CET Report this content
BioInvent, known for its innovative cancer immunotherapies, is expanding its partnership with MSD to test BI-1607 in c... |
| 01.07.2024 | BioStock: Top oncologist underscores BioInvent’s potential for “Immunotherapy 2.0” | BioStock: Top oncologist underscores BioInvent’s potential for “Immunotherapy 2.0”
Mon, Jul 01, 2024 08:15 CET Report this content
BioInvent recently announced promising clinical data for its lead cancer immunotherapy candidates, BI-1808 an... |
| 30.05.2024 | BioStock: BioInvent to present promising clinical data at ASCO and EHA | BioStock: BioInvent to present promising clinical data at ASCO and EHA
Thu, May 30, 2024 12:43 CET Report this content
In the coming weeks, BioInvent is set to present three significant data sets at the American Society for Clinical Oncolog... |
| 30.04.2024 | BioInvent evaluating Attana Technology | BioInvent evaluating Attana Technology
Tue, Apr 30, 2024 11:45 CET Report this content
BioInvent and Attana has signed a three-month evaluation agreement. BioInvent is a clinical-stage company that discovers and develops antibodies for canc... |
| 11.03.2024 | BioStock: BioInvent’s CEO comments on the study success in China | BioStock: BioInvent’s CEO comments on the study success in China
Mon, Mar 11, 2024 12:31 CET Report this content
BioInvent’s partner in China, CASI Pharmaceuticals, has announced preliminary encouraging efficacy data for BioInvent’s lead dr... |
| 29.05.2023 | Find your next investment at the BioStock Life Science Spring Summit on May 30 and 31! | Find your next investment at the BioStock Life Science Spring Summit on May 30 and 31!
Mon, May 29, 2023 09:45 CET Report this content
It is finally time for BioStock Life Science Spring Summit 2023! Around 30 companies from a wide range of... |
| 31.01.2023 | Change in the Number of Shares and Votes in BioInvent International AB | LUND, SE / ACCESSWIRE / January 31, 2023 / BioInvent International BINV
Lund, Sweden, January 31, 2023 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that the company's total number of shares a... |
| 17.01.2023 | BioInvent Selected to The Leukemia & Lymphoma Society’s Therapy Acceleration Program and Receives $3 million Strategic Equity Investment | Strategic equity investment of USD 3 million to support clinical advancement of BI-1206 in Non-Hodgkin's Lymphoma
Supports also clinical development of BI-1808 in cutaneous T-cell lymphoma
LLS TAP is a strategic funding initiative to accele... |
| 18.11.2022 | BioInvent Receives FDA IND Approval for Anti-FcyRIIB Antibody BI-1607 | LUND, SE / ACCESSWIRE / November 18, 2022 / BioInvent International (STO:BINV)
Phase 1/2a trial in combination with trastuzumab is cleared to be extended to U.S. centers
BioInvent has four drugs in five clinical trials, underlining producti... |
| 25.08.2022 | BioInvent International AB: Interim Report January-June 2022 | LUND, SWEDEN / ACCESSWIRE / August 25, 2022 / BioInvent International (STO:BINV)
"The second quarter 2022 was eventful for BioInvent, delivering a deal with the US biotech company Exelixis, positive progress in our clinical portfolio a... |
| 29.07.2022 | Change in the Number of Shares and Votes in BioInvent International AB | LUND, SWEDEN / ACCESSWIRE / July 29, 2022 / BioInvent International (STO:BINV)
Lund, Sweden - July 29, 2022 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that the company's total number of sha... |
| 16.06.2022 | Exelixis taps into cancer antibody discoverer out of Sweden | Exelixis is doling out $25 million to snag rights to choose three targets found by BioInvent.
The California cancer drugmaker is linking arms with the Swedish biotech — both founded in the mid 90s — to expand its suite of an... |
| 28.04.2022 | BioInvent Receives Milestone Payment from Bayer/Hope Medicine Licensing Agreement | LUND, SWEDEN / ACCESSWIRE / April 28, 2022 / BioInvent International (STO:BINV)
Lund, Sweden - April 28, 2022 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and deve... |
| 27.04.2022 | BioInvent International AB: Interim Report January-March 2022 | LUND, SE / ACCESSWIRE / April 27, 2022 / BioInvent International (STO:BINV)
"The exciting translational data presented on BI-1808 at AACR clearly show why we are so enthusiastic about our ongoing clinical studies in solid tumors. It is... |
| 07.04.2022 | BioInvent International AB publishes Annual Report 2021 | LUND, SE / ACCESSWIRE / April 7, 2022 / BioInvent International (STO:BINV)
BioInvent International AB (publ) (Nasdaq Stockholm: BINV) today announced that the Annual Report for 2021 has been published. The Annual Report is attached to this ... |
| 28.03.2022 | Notice to Annual General Meeting in BioInvent International AB | LUND, SWEDEN / ACCESSWIRE / March 28, 2022 / BioInvent International (STO:BINV)
The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting to be held at 4.00 p.m., Thu... |
| 20.01.2022 | CASI PHARMACEUTICALS PARTNER, BIOINVENT, ANNOUNCES BI -1206 GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA | ROCKVILLE, Md and LUND, Sweden, Jan. 20, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announc... |
| 04.11.2021 | (R) BioInvent to show further positive BI-1206 clinical data in December at ASH 2021 | BioInvent to show further positive BI-1206 clinical data in December at ASH 2021 4 nov. 2021 14:00:00
Regulatory
BI-1206 restores rituximab activity in relapsed or refractory patients
Demonstrates ORR 50%, DCR 58%, with complete responses l... |
| 28.10.2021 | 28/10/2021 BioInvent Interim Report, January 1 - September 30, 2021 | Q3
INTERIM REPORT JANUARY 1 - SEPTEMBER 30, 2021
BioInvent's CEO:
"The powerful combination of BioInvent's R&D and in-house manufacturing provides invaluable support to our clinical development and facilitates the execution of our ... |
| 25.10.2021 | BioInvent International : appoints immunotherapy expert Alexander Eggermont to Scientific Advisory Board | Holds extensive expertise in surgical oncology, immunotherapy, and drug development
Will provide valuable input as BioInvent further expands clinical pipeline of cancer drugs
Lund, Sweden – October 25, 2021 – BioInvent International AB (“Bi... |
| 26.08.2021 | BioInvent International : 26/08/2021 BioInvent Interim Report, January 1 - June 30, 2021 | Q2
INTERIM REPORT JANUARY 1 - JUNE 30, 2021
CEO Martin Welschof on the new agreement with Merck:
"We are very pleased we have reached a second collaboration with MSD (Merck) that supports the expansion of the ongoing clinical trial pro... |
| 26.08.2021 | BioInvent International AB: Interim report January-June 2021 | BioInvent International AB: Interim report January-June 2021 Thu, Aug 26, 2021 08:00 CET
“We are very pleased we have reached a second collaboration with MSD (Merck) that supports the expansion of the ongoing clinical trial program with our... |
| 06.08.2021 | BioInvent Announces Second Clinical Trial Collaboration and Supply Agreement to Evaluate BI-1808 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors | BioInvent Announces Second Clinical Trial Collaboration and Supply Agreement to Evaluate BI-1808 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors Fri, Aug 06, 2021 11:15 CET
Anti-TNFR2 antibody targets Tr... |
| 06.08.2021 | BioInvent Announces Second Clinical Trial Collaboration and Supply Agreement to Evaluate BI-1808 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors | LUND, Sweden, Aug. 6, 2021 /PRNewswire/ -- BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that it has entered into a second clinical trial collaboration and supply agreement with MSD, a tradename... |
| 27.05.2021 | BioInvent and Transgene receive IND approval from the U.S. FDA for BT-001, a novel oncolytic virus for the treatment of solid tumors | BioInvent and Transgene receive IND approval from the U.S. FDA for BT-001, a novel oncolytic virus for the treatment of solid tumors Thu, May 27, 2021 08:30 CET
Lund, Sweden and Strasbourg, France – May 27, 2021 – BioInvent International AB... |
| 28.04.2021 | BIOINVENT INTERNATIONAL AB (PUBL)
BioInvent International : Interim Report, January 1 - March 31, 2021 | Q1
INTERIM REPORT JANUARY 1 - MARCH 31, 2021
Events in the quarter
PROJECT UPDATES
(R) BioInvent Phase 1/2a data suggest BI-1206 restores activity of rituximab in re- lapsed non-Hodgkin's lymphoma patients.
BioInvent enrolled first patient ... |
| 28.04.2021 | BioInvent International : Interim Report, January 1 - March 31, 2021 | Q1
INTERIM REPORT JANUARY 1 - MARCH 31, 2021
Events in the quarter
PROJECT UPDATES
(R) BioInvent Phase 1/2a data suggest BI-1206 restores activity of rituximab in re- lapsed non-Hodgkin's lymphoma patients.
BioInvent enrolled first patient ... |
| 07.04.2021 | BioInvent receives IND approval for Phase I/IIa trial of anti-TNFR2 antibody BI-1808 | LUND, Sweden, April 7, 2021 /PRNewswire/ -- BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) for the... |
| 07.04.2021 | BioInvent receives IND approval for Phase I/IIa trial of anti-TNFR2 antibody BI-1808 | - Study explores potential in solid tumors and cutaneous T-cell lymphoma
- BI-1808 is one of three BioInvent drug candidates in clinical development
LUND, Sweden, April 7, 2021 /PRNewswire/ -- BioInvent International AB ("BioInvent&quo... |
| 31.03.2021 | Change in the number of shares and votes in BioInvent International AB | Change in the number of shares and votes in BioInvent International AB Wed, Mar 31, 2021 08:30 CET
Lund, Sweden, March 31, 2021 – BioInvent International AB (publ) (Nasdaq Stockholm: BINV) today announced that the company’s total number of ... |
| 23.02.2021 | BIOINVENT INTERNATIONAL AB (PUBL)
BioInvent International : BioInvent International Financial Statement January 1 - December 31, 2020 | BioInvent International Financial Statement January 1 - December 31, 2020
Promising early interim efficacy data on our lead drug candidate 'BioInvent has started 2021 with significant positive momentum We reported promising interim efficacy... |
| 23.02.2021 | BioInvent International : BioInvent International Financial Statement January 1 - December 31, 2020 | BioInvent International Financial Statement January 1 - December 31, 2020
Promising early interim efficacy data on our lead drug candidate 'BioInvent has started 2021 with significant positive momentum We reported promising interim efficacy... |
| 27.08.2020 | BioInvent : Interim Report January 1 - June 30, 2020 | LUND, Sweden, Aug. 27, 2020 /PRNewswire/ -- "BioInvent is fully focused on moving our clinical projects forward. Our successful financing of SEK 625 million has strengthened our institutional investor base and is truly transformative f... |
| 27.08.2020 | BIOINVENT INTERNATIONAL AB (PUBL)
BioInvent International : BioInvent Interim Report January 1 – June 30, 2020 | 'BioInvent is fully focused on moving our clinical projects forward. Our successful financing of SEK 625 million has strengthened our institutional investor base and is truly transformative for the company as it allows us to broaden and dev... |
| 09.06.2020 | BIOINVENT INTERNATIONAL AB (PUBL)
BioInvent International publ : successfully completes a directed share issue of approximately SEK 487 million (approximately EUR 47 million) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, UNITED KINGDOM OR ANY OTHER JURISDICTION WHER... |
